Isoniazid
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | NYDRAZID | — | 1952-09-29 | fda.gov ↗ |
Trials 120 · started per year
Also used as a comparator or background therapy in 101 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT07058090 Comparator | Jul → Dec 2025 overdue | drug-induced liver injury, tuberculosis | Liaquat National Hospital & Medical College | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05592223 Comparator | Dec 2022 → Aug 2023 | tuberculosis | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT04424264 Background | Dec 2019 → Oct 2020 | HIV infectious disease, tuberculosis | Professor Francois Venter | Completed | No outcome recorded |
| Phase 1 | NCT02832778 Background | Nov 2016 → Jan 2018 | HIV infectious disease | St Stephens Aids Trust | Unknown | No outcome recorded |
| Phase 1 | NCT01838200 Background | Mar 2014 → Aug 2015 | metastatic melanoma | Ludwig Institute for Cancer Research | Terminated | No outcome recorded |
| Phase 1 | NCT00004736 Background | — | HIV infectious disease, tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07124559 Background | Jul 2026 → Jan 2028 expected | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT03678688 Comparator | Oct 2018 → Feb 2022 | pulmonary tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02958709 Background | Feb 2017 → Nov 2020 | meningeal tuberculosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1/2 | NCT00396084 Comparator | Feb 2004 → Nov 2007 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 243 trials | ||||||
| Phase 2 | NCT07467252 Comparator | Sep 2026 → Dec 2027 expected | pulmonary tuberculosis | Ministry of Health, Saudi Arabia | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07656012 Background | Sep 2026 → Sep 2030 expected | tuberculosis | University of Wisconsin, Madison | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07595042 Background | Jul 2026 → Jun 2029 expected | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07350174 Comparator | Mar 2026 → Mar 2028 expected | meningeal tuberculosis | BioVersys AG | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07303699 Background | Jan 2026 → Mar 2027 expected | pulmonary tuberculosis | Obafemi Awolowo University Teaching Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07073638 Background | Oct 2025 → Sep 2026 expected | pulmonary tuberculosis | Thirty Respiratory Limited | Recruiting | No outcome recorded |
| Phase 2 | NCT06446245 Background | Aug 2025 → Nov 2027 expected | meningeal tuberculosis | National University Hospital, Singapore | Recruiting | No outcome recorded |
| Phase 2 | NCT06917495 Background | Apr 2025 → Dec 2027 expected | tuberculosis, spinal | Shandong University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06192160 Background | Mar 2025 → Nov 2026 expected | pulmonary tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 2 | NCT06748937 Comparator | Mar 2025 → Mar 2026 overdue | pulmonary tuberculosis | TASK Applied Science | Recruiting | No outcome recorded |
| Phase 2 | NCT05630872 Background | Feb 2024 → May 2025 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT06114628 Comparator | Jan 2024 → Feb 2027 expected | pulmonary tuberculosis | University College, London | Recruiting | No outcome recorded |
| Phase 2 | NCT06199921 Comparator | Jan 2024 → Mar 2026 overdue | pulmonary tuberculosis | Obafemi Awolowo University Teaching Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05556746 Comparator | Nov 2023 → Jun 2025 overdue | HIV infectious disease, pulmonary tuberculosis | Brigham and Women's Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06224036 Comparator | Oct 2023 → Mar 2024 | drug-resistant tuberculosis | Beijing Chest Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06058299 Comparator | Oct 2023 → Dec 2024 overdue | pulmonary tuberculosis | Global Alliance for TB Drug Development | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05534750 Comparator | Apr 2023 → Apr 2026 overdue | multidrug-resistant tuberculosis | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 2 | NCT05473195 Comparator | Dec 2022 → Apr 2024 | primary pulmonary tuberculosis | TASK Applied Science | Completed | No outcome recorded |
| Phase 2 | NCT04694586 Background | Nov 2022 → May 2024 | pulmonary tuberculosis | University Hospital, Linkoeping | Suspended | No outcome recorded |
| Phase 2 | NCT05221502 Comparator | Apr 2022 → Apr 2024 | pulmonary tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04930744 Background | Aug 2021 → Apr 2025 | coinfection, pulmonary tuberculosis | University of Massachusetts, Worcester | Completed | No outcome recorded |
| Phase 2 | NCT03891901 Background | Oct 2020 → Aug 2022 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT04504851 Background | Aug 2020 → Mar 2021 | pulmonary tuberculosis | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT04176250 Comparator | Jan 2020 → Oct 2022 | pulmonary tuberculosis | Gates Medical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT03927313 Background | Jun 2019 → Mar 2021 | HIV infectious disease, meningeal tuberculosis | University of Cape Town | Completed | No outcome recorded |
| Phase 2 | NCT03563599 Comparator | Jul 2018 → Sep 2019 | tuberculosis | Qurient Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT03334734 Comparator | Dec 2016 → Sep 2017 | tuberculosis | Nearmedic Plus LLC | Terminated | No outcome recorded |
| Phase 2 | NCT02836483 Comparator | Dec 2016 → Jul 2019 | pulmonary tuberculosis | LigaChem Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03281226 Comparator | Dec 2016 → Jun 2019 | AIDS, pulmonary tuberculosis | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | Unknown | No outcome recorded |
| Phase 2 | NCT01589497 Comparator | Jun 2015 → Jan 2016 | tuberculosis | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 2 | NCT02256696 Background | Apr 2015 → May 2022 | pulmonary tuberculosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT02279875 Comparator | Nov 2014 → Nov 2016 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 2 | NCT02193776 Comparator | Oct 2014 → Feb 2016 | tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 2 | NCT01601626 Background | Jul 2013 → Jan 2017 | HIV infectious disease, tuberculosis | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Terminated | No outcome recorded |
| Phase 2 | NCT02121314 Comparator | Jul 2013 → Apr 2014 | tuberculosis | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 2 | NCT01785186 Background | Apr 2013 → Sep 2014 | pulmonary tuberculosis | Michael Hoelscher | Completed | No outcome recorded |
| Phase 2 | NCT01516203 Comparator | Dec 2012 → Dec 2013 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT01225640 Comparator | Aug → Dec 2011 | tuberculosis | Sequella, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01215851 Comparator | Oct 2010 → May 2011 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 2 | NCT00728507 Background | Nov 2009 → Apr 2013 | tuberculosis | Johns Hopkins University | Terminated | No outcome recorded |
| Phase 2 | NCT00144417 Comparator | Feb 2006 → Jun 2007 | tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2 | NCT00164463 Comparator | Jul 2004 → Aug 2007 | tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2 | NCT00140309 Background | Jul 2003 → Dec 2005 | pulmonary tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT05766267 Comparator | Nov 2023 → Dec 2026 expected | pulmonary tuberculosis | Centers for Disease Control and Prevention | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT06618573 Comparator | Aug 2022 → Dec 2025 overdue | systemic lupus erythematosus, tuberculosis | Padjadjaran University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03474029 Comparator | Aug 2019 → Dec 2029 expected | latent tuberculosis infection | Centers for Disease Control and Prevention | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03338621 Comparator | Jul 2018 → Jul 2021 | multidrug-resistant tuberculosis, pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 2/3 | NCT03474198 Background | Mar 2018 → Jan 2022 | pulmonary tuberculosis | University College, London | Completed | No outcome recorded |
| Phase 2/3 | NCT02467608 Background | Dec 2012 → Jan 2019 | pulmonary tuberculosis | Orient Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT00495326 Background | Dec 2007 → Apr 2011 | AIDS, tuberculosis | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 321 trials | ||||||
| Phase 3 | NCT07076225 Comparator | Jul 2025 → Jan 2030 expected | pulmonary tuberculosis | Shenzhen Third People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06905522 Comparator | Jun 2025 → Jan 2029 expected | pulmonary tuberculosis | Shenzhen Third People's Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06022146 Comparator | Sep 2023 → Sep 2026 expected | latent tuberculosis infection | Huashan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT04951986 Background | Aug 2021 → Dec 2025 overdue | HIV infectious disease, tuberculosis | University of Cape Town | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04260477 Comparator | Mar 2021 → Jun 2025 overdue | multidrug-resistant tuberculosis, pulmonary tuberculosis | Institute of Tropical Medicine, Belgium | Recruiting | No outcome recorded |
| Phase 3 | NCT04145258 Background | Feb 2021 → Sep 2026 expected | meningeal tuberculosis | ANRS, Emerging Infectious Diseases | Recruiting | No outcome recorded |
| Phase 3 | NCT04485156 Background | Sep 2020 → Aug 2025 overdue | pulmonary tuberculosis | Seoul National University Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04062201 Comparator | Aug 2019 → Apr 2024 | extensively drug-resistant tuberculosis, multidrug-resistant tuberculosis, rifampicin-resistant tuberculosis | Wits Health Consortium (Pty) Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02581527 Background | Feb 2017 → Jan 2022 | pulmonary tuberculosis | St George's, University of London | Completed | No outcome recorded |
| Phase 3 | NCT02980016 Comparator | Nov 2016 → Oct 2019 | HIV infectious disease, tuberculosis | The Aurum Institute NPC | Completed | No outcome recorded |
| Phase 3 | NCT02563327 Background | May 2016 → Aug 2021 | tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 3 | NCT02342886 Comparator | Feb 2015 → Jan 2018 | multidrug-resistant tuberculosis, pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 3 | NCT02153528 Background | Nov 2014 → Aug 2017 | pulmonary tuberculosis | Damien Foundation | Completed | No outcome recorded |
| Phase 3 | NCT02208427 Comparator | Aug 2014 → Dec 2016 | latent tuberculosis infection | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01761201 Comparator | Jan 2012 → Feb 2014 | disease related to solid organ transplantation, latent tuberculosis infection | Andalusian Public Foundation for Health Research in Seville | Terminated | No outcome recorded |
| Phase 3 | NCT00170209 Comparator | Aug 2011 → Nov 2014 | latent tuberculosis infection | McGill University | Completed | No outcome recorded |
| Phase 3 | NCT00931736 Comparator | Aug 2009 → Apr 2017 | latent tuberculosis infection | McGill University | Completed | No outcome recorded |
| Phase 3 | NCT00571753 Comparator | Jun 2008 → Dec 2011 | pulmonary tuberculosis | University of Cologne | Terminated | No outcome recorded |
| Phase 3 | NCT00128206 Comparator | Nov 2004 → Oct 2008 | tuberculosis | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT00057122 Comparator | Sep 2002 → Nov 2008 | HIV infectious disease, tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT00023452 Comparator | Jun 2001 → Oct 2010 | tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 410 trials | ||||||
| Phase 4 | NCT05021731 Comparator | Apr 2024 → Apr 2025 | kidney failure, latent tuberculosis infection | Miguel Santin | Unknown | No outcome recorded |
| Phase 4 | NCT06403943 Background | May 2023 → Oct 2026 expected | pulmonary tuberculosis | Beijing Chest Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT03867136 Comparator | Jun 2020 → Aug 2024 | multidrug-resistant tuberculosis | Huashan Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03278483 Comparator | Feb 2019 | tuberculosis, type 2 diabetes mellitus | National Institute of Public Health, Mexico | Completed | No outcome recorded |
| Phase 4 | NCT06874725 Comparator | Apr 2018 → Apr 2024 overdue | latent tuberculosis infection | Taichung Veterans General Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03561753 Comparator | Dec 2017 → Dec 2019 | pulmonary tuberculosis | Shanghai Pulmonary Hospital, Shanghai, China | Completed | No outcome recorded |
| Phase 4 | NCT02231229 Comparator | Jul 2014 → Jul 2018 | tuberculosis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4 | NCT02331823 Comparator | Jun 2013 → Dec 2015 | pulmonary tuberculosis | Shanghai Pulmonary Hospital, Shanghai, China | Unknown | No outcome recorded |
| Phase 4 | NCT03498534 Comparator | Sep → Dec 2012 | diabetes mellitus, latent tuberculosis infection | National Institute of Public Health, Mexico | Withdrawn | No outcome recorded |
| Phase 4 | NCT01223534 Comparator | Jul 2010 → Feb 2016 | latent tuberculosis infection | Hospital Universitari de Bellvitge | Completed | No outcome recorded |
| Phase not applicable9 trials | ||||||
| — | NCT04187469 Background | Mar 2020 → Feb 2023 | pulmonary tuberculosis | Fifth Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT02554318 Background | Nov 2013 → Feb 2015 | pulmonary tuberculosis | University of Giessen | Completed | No outcome recorded |
| — | NCT01677871 Comparator | Sep 2012 → Sep 2014 | tuberculosis | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT01344148 Background | Feb 2009 → Jun 2011 | AIDS | Shanghai Public Health Clinical Center | Unknown | No outcome recorded |
| — | NCT00737724 Background | Mar 2008 → Feb 2011 | AIDS, tuberculosis | National Institute of Respiratory Diseases | Terminated | No outcome recorded |
| — | NCT00164450 Comparator | Sep 2005 → Aug 2008 | tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| — | NCT00130325 Comparator | Oct 2004 → Oct 2008 | tuberculosis | Medical Research Council Unit, The Gambia | Completed | No outcome recorded |
| — | NCT00023387 Background | Mar 2000 → May 2001 | tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| — | NCT00004740 Background | Feb 1995 → ? | tuberculosis | National Institute on Drug Abuse (NIDA) | Unknown | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 225 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Isoniazid | “empiric initiation of the enhanced spectrum antimicrobial therapy regimen (rifampin, isoniazid, linezolid, and levofloxacin) for 14 days plus standard care which includes...” NCT07332325 ↗221“INTERVENTIONS: Patients were randomized to receive daily treatment with 4 drugs (rifampicin, isoniazid, pyrazinamide, ethambutol) given as an FDC (n = 798 patients) or...” PMID 21486974 ↗ Apr 2011 “This product is a compound preparation, consisting of 0.15g of rifampicin (C43H58N4O12), 0.075g of isoniazid (C6H7N3O), 0.4g of pyrazinamide (C5H5N3O), and 0.275g of ethambutol...” NCT06224036 ↗ “Increased doses of rifampicin (R) to 35±5 mg/kg daily and isoniazid (H) 10±2 mg/kg daily together with standard-dose of pyrazinamide (Z) 20-30 mg/kg daily + ethambutol (E)...” NCT04738812 ↗ “FDC intensive phase containing 150 mg of rifampicin, 75 mg of isoniazid not 300mg, 400 mg of pyrazinamide, and 275 mg of ethambutol, while FDC continuation phase containing...” NCT05005637 ↗ “The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.” NCT03561753 ↗ “This study aimed to quantify the influence of food on the pharmacokinetics of isoniazid, rifampicin, ethambutol and pyrazinamide in TB patients starting anti-TB treatment.” PMID 26661397 ↗ Dec 2015 “SOC plus 6 months of tuberculosis treatment (isoniazid, rifampicin, pyrazinamide, and ethambutol for 2 months, plus isoniazid and rifampicin for 4 subsequent months)” PMID 42468541 ↗ Jul 2026 “provision of tuberculin skin tests, and use of isoniazid preventive therapy in Brazilian HIV clinics significantly reduced incident tuberculosis and death” PMID 23954450 ↗ Aug 2013 “RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months” NCT04117698 ↗ “using regimens containing isoniazid (INH \[H\]), rifampin (RIF \[R\]), pyrazinamide (PZA \[Z\]), moxifloxacin (MXF \[M\]), and ethambutol (EMB \[E\]).” NCT02371681 ↗ “8 weeks of daily isoniazid, rifapentine, moxifloxacin and pyrazinamide, followed by 9 weeks of daily isoniazid, rifapentine and moxifloxacin.” NCT07608172 ↗ “Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained” NCT02153528 ↗ “Rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight)” NCT03281226 ↗ “including rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 15 - 20 mg/kg, ± pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day” NCT06446245 ↗ “Isoniazid \[H\] / rifampicin \[R\] / pyrazinamide \[Z\] / ethambutol \[E\] (HRZE), a fixed dose combination tablet QD for 14 days” NCT04176250 ↗ “8 weeks of isoniazid, pyrazinamide, rifapentine, and moxifloxacin, followed by 9 weeks of isoniazid, rifapentine and moxifloxacin” NCT04856644 ↗ “Patients with probable or definite TB meningitis (TBM) will all receive isoniazid and pyrazinamide at standard doses for 8 weeks.” NCT02958709 ↗ “Oral chemoprophylaxis will be standard of care - either 6 months of Isoniazid or 3 months of weekly Isoniazid and Rifapentine” NCT05330884 ↗ “Two months of isoniazid (H), ethambutol (E), rifampicin (R) and Pyrazinamide (Z) followed by HR(E) for another two months” NCT06727864 ↗ “Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months” NCT01677871 ↗ “10mg/kg oral rifampicin, 5mg/kg oral isoniazid, 15mg/kg oral ethambutol, 25mg/kg oral pyrazinamide daily for 56 days.” NCT03927313 ↗ “Dosage strength per tablet is 150 mg Rifampicin (R)/75 mg Isoniazid (H)/400 mg Pyrazinamide (Z)/275 mg Ethambutol (E)” NCT01225640 ↗ “Each tablet of Rifafour e-275® contains 150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide and 275mg ethambutol.” NCT04044001 ↗ “isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + placebo of aspirin” NCT04145258 ↗ “Isoniazid (5 mg/kg/day); Rifampicin (10 mg/kg/day); Pyrazinamide (30 mg/kg/day); Ethambutol (20 mg/kg/day).” NCT07350174 ↗ “isoniazid 75 mg plus rifampicin 150 mg plus pyrazinamide 400 mg plus ethambutol 275 mg combination tablets” NCT03338621 ↗ “or an active control of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) or linezolid 600 mg BID.” PMID 34871098 ↗ Dec 2021 “Isoniazid (H) + rifampicin (R) + pyrazinamide (Z), ethambutol (E) for 8 weeks followed by HR for 18 weeks” NCT06058299 ↗ “Each tablet contains 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol.” NCT03678688 ↗ “Anti-Tb Therapy: 2HREZ-4HRifb(H:Isoniazid，R:Rifampicin，E:Ethambutol，Z：pyrazinamide，Rifb:Rifabutin)” NCT01344148 ↗ “each tablet containing 150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, and 275mg ethambutol” NCT01215851 ↗ “weekly oral Rifapentine 15 mg/kg (up to 900mg) plus Isoniazid 15 mg/kg (up to 900mg) for 12 doses” NCT02430259 ↗ “isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg combination tablets” NCT04694586 ↗ “Participants will receive Rifapentine 600 mg daily and isoniazid (INH) 300 mg daily for 4 weeks.” NCT04703075 ↗ “isoniazid 75 mg (H), rifampicin 150 mg (R), pyrazinamide 400 mg (Z), ethambutol 275 mg (E)” NCT06041919 ↗ “isoniazid ≤55kg 225mg daily, 55-71kg 300mg daily, \>71kg 375mg daily; pyrazinamide” NCT05401071 ↗ “daily rifapentine (R) and moxifloxacin (M) plus isoniazid (H) and pyrazinamide (P)” NCT05630872 ↗ “Rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg” NCT02832778 ↗ “Isoniazid (H) , Rifampicin (R), Pyrazinamide (Z) and Ethambutol (E)” NCT06153069 ↗ “New high-dose isoniazid retreatment regimen (6EH³RZ) - H 15mg/kg” NCT03862248 ↗ “RHZE (R=rifampicin: H=isoniazid: Z=pyrazinamide: E=ethambutol)” NCT03563599 ↗ “8-month regimen of isoniazid, rifampicin, and streptomycin” PMID 29519716 ↗ Mar 2018 “once-weekly rifapentine (RPT) and isoniazid (INH) (3HP)” NCT05122767 ↗ “rifampicin, rifabutin, isoniazid, high dose isoniazid” NCT03237182 ↗ “Ethambutol; isoniazid; rifampicin; pyrazinamide” NCT04260477 ↗ “High-dose isoniazid 600mg daily” NCT03867136 ↗ “of Isoniazid (RIMIFON®)” NCT05534750 ↗ “Isoniazid 600mg daily” NCT02120638 ↗ “isoniazid (H / INH)” NCT02231229 ↗ “Isoniazid (0.3g)” NCT06403943 ↗ “Drug: Isoniazid” NCT01761201 ↗ “Isoniazid” NCT00728546 ↗ “isoniazid” NCT00737724 ↗ “Isoniazid” NCT02099240 ↗ |
| Known as | Generic name: Isoniazid. | “Generic name: Isoniazid.” NCT01761201 ↗ |
| Known as | INH | “This study is a phase I, single-center, open label, randomized controlled clinical trial assessing the effect of pre-clearance of latent Mycobacterium tuberculosis (MTB) by...” NCT01119521 ↗38“To evaluate and compare the safety and effectiveness of a one-year course of isoniazid (INH) versus a two-month course of rifampin plus pyrazinamide for the prevention of...” NCT00000638 ↗ “The investigators hypothesize that short-course (4-week) daily isoniazid/rifapentine (INH/RPT) (1HP) is not inferior to standard -course (12 weeks) INH/RPT weekly regimen (3HP)...” NCT03785106 ↗ “Standard of care involves Isoniazid Prevention Therapy (IPT) - the administration of Isoniazid (INH) to individuals with latent infection with M. tuberculosis in order to...” NCT01926379 ↗ “Patients will be screened to confirm TBM diagnosis, will receive 8 weeks of study treatment, and then will receive isoniazid (INH)/rifampicin for an additional 40 weeks, to...” NCT02958709 ↗ “Many people living with human immunodeficiency virus (PLWH) require TB treatment with isoniazid (INH) and rifampicin (RIF), which affect cytochrome P450 and antiretroviral exposure.” PMID 30084943 ↗ Jan 2019 “Isoniazid (INH) is a first-line antituberculous medication discovered in 1952 and used in the prevention (alone) and treatment (in combination) of tuberculosis.” NCT00816426 ↗ “Randomized controlled trial (RCT) of isoniazid (INH) vs. no INH to prevent Mycobacterium tuberculosis infection in HIV-exposed uninfected (HEU) infants.” NCT02613169 ↗ “compared with an isoniazid (INH) control arm in patients with newly-diagnosed sputum smear-positive pulmonary tuberculosis (TB).” NCT00396084 ↗ “To evaluate the safety and effectiveness of a 6-month course of isoniazid ( INH ) in the prevention of clinical tuberculosis.” NCT00000959 ↗ “Isoniazid prophylaxis:300 mg of INH once a day before breakfast for six months, starting one month after study inclusion” NCT00495651 ↗ “The Arkansas colorimetric method monitors adherence to isoniazid (INH) by the detection of INH metabolites in urine.” PMID 24903787 ↗ May 2014 “Participants will receive Rifapentine 600 mg daily and isoniazid (INH) 300 mg daily for 4 weeks.” NCT04703075 ↗ “Rifapentine (RPT) 900 mg and isoniazid (INH) 900 mg given once-weekly for 12 weeks (3HP).\*” NCT03474029 ↗ “2 months of daily isoniazid (INH), rifampicin, pyrazinamide and ethambutol” NCT00130247 ↗ “widespread INH (Isoniazid) prophylaxis therapy in HIV-infected patients” NCT00107887 ↗ “receiving Isoniazid (INH)10-20 mg/kg orally once a day for 96 weeks” NCT00080119 ↗ “isoniazid (INH) (900 mg orally) given twice weekly for 9 months” NCT00128206 ↗ “once-weekly rifapentine (RPT) and isoniazid (INH) (3HP)” NCT05122767 ↗ “Isoniazid (INH) has very high bactericidal activity” NCT07708779 ↗ “treatment with isoniazid (INH) for 9 months” NCT05411744 ↗ “isoniazid (INH) at high & normal dosages” NCT00513396 ↗ “including isoniazid (INH) prophylaxis” NCT06618573 ↗ “Isoniazid (INH) daily for 9 months” NCT06874725 ↗ “INH 300 mg orally once daily” NCT01380080 ↗ “Isoniazid 300 mg po OD (INH)” NCT05473195 ↗ “isoniazid (INH) prophylaxis” NCT01087190 ↗ “isoniazid (INH, 900 mg)” NCT04600167 ↗ “isoniazid (INH \[H\])” NCT02371681 ↗ “Drug: Isoniazid (INH)” NCT05383742 ↗ “isoniazid (H / INH)” NCT02231229 ↗ “1.Isoniazid (INH)” NCT00463086 ↗ “Isoniazid (INH)” NCT01494038 ↗ “Isoniazid (INH)” NCT03568383 ↗ “Isoniazid (INH)” NCT03886701 ↗ “Isoniazid (INH)” NCT01404312 ↗ “Isoniazid (INH)” NCT03510468 ↗ “Isoniazid (INH)” NCT04272242 ↗ “Isoniazid (INH)” NCT02651259 ↗ |
| Known as | Isoniazid (H) | “Isoniazid (H)” NCT07656012 ↗ |
| Known as | Isoniazid I INH | “Isoniazid I INH” NCT03900858 ↗ |
| Known as | isoniazid tablets | “isoniazid tablets” NCT02331823 ↗ |
| Known as | isonicotinic acid hydrazine | “This study is a phase I, single-center, open label, randomized controlled clinical trial assessing the effect of pre-clearance of latent Mycobacterium tuberculosis (MTB) by...” NCT01119521 ↗ |
| Known as | Rifinah | “Isoniazid (Rifinah)” NCT00728546 ↗ |
| Known as | RIMIFON | “of Isoniazid (RIMIFON®)” NCT05534750 ↗ |
| Action | Inhibit | “Its primary action is to inhibit the synthesis of long-chain mycolic acids” NCT02409290 ↗ |
| Modality | Small molecule | “This product is a compound preparation, consisting of 0.15g of rifampicin (C43H58N4O12), 0.075g of isoniazid (C6H7N3O)” NCT06224036 ↗ |
| Route | Oral | “self-administer oral isoniazid” NCT00004740 ↗ |